Should all MCI with Alzheimer's biological diagnosis receive anti-amyloid therapy? - PubMed
3 months ago
- #Alzheimer's disease
- #mild cognitive impairment
- #anti-amyloid therapy
- The debate centers on whether anti-amyloid therapy should be universally prescribed for MCI patients with Alzheimer's biological markers, given the variability in progression to dementia.
- Epidemiological data shows that over half of MCI patients, even those with amyloid/tau biomarkers, do not progress to dementia over long-term follow-up.
- Anti-amyloid therapies, while groundbreaking, come with high costs, significant risks like amyloid-related imaging abnormalities, and uncertain long-term benefits.
- Indiscriminate use of these therapies could expose many patients to unnecessary risks and strain healthcare systems.
- The need for risk-stratified treatment pathways is emphasized, integrating genetic, clinical, and biomarker data for better prognostication.
- A call for interdisciplinary dialogue involving neurology, geriatrics, bioethics, health economics, and patient advocacy to ensure ethical and equitable implementation of treatments.